FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Gen Virol / Recombinant baculovirus-synthesized African horsesickness vi...
The Journal of general virology1996; 77 ( Pt 9); 2053-2057; doi: 10.1099/0022-1317-77-9-2053

Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.

Abstract: African horsesickness virus serotype 4 (AHSV-4) outer-capsid proteins VP2 or VP2 and VP5, prepared from single or dual recombinant baculovirus expression vectors grown in Sf9 insect cells, were administered in different amounts to horses and the neutralizing antibody responses were measured. Control and vaccinated horses were challenged with virulent AHSV-4 6 months later and monitored post challenge. The results indicated that two inoculations of extracts containing VP2 and VP5, or VP2 alone, in doses of 5 micrograms VP2 or more per horse, were sufficient to elicit protection against African horsesickness (AHS) disease. The recombinant VP2 protein is a potential candidate vaccine for AHS in horses.
Get Full Text
Publication Date: 1996-09-01 PubMed ID: 8811002DOI: 10.1099/0022-1317-77-9-2053Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses a study where the outer-capsid proteins of the deadly African Horsesickness Virus (AHSV) were used to generate a sufficient immune response in horses, offering potential for a new vaccine.

Introduction to African Horsesickness Virus (AHSV)

  • The African horsesickness virus is a serious equine disease; it is extremely fatal and spreads rapidly among horses.
  • The virus is primarily spread through blood-feeding insects, especially certain species of Culicoides biting midges.
  • Existing treatments are not fully effective, therefore, a safe and reliable vaccine is highly desirable to protect horses from this disease.

Function of Outer-Capsid Proteins in Vaccine

  • The researchers focused on two proteins found on the surface (outer-capsid) of AHSV, named VP2 and VP5. These proteins play crucial roles in the infection process.
  • VP2 is particularly significant because it determines the virus’s serotype (the version of the virus) and is a primary target of the body’s immune response.
  • As these proteins stimulate the immune system, they were used to generate an immune response in the study’s test subjects, the horses.

Experiment Process and Results

  • In this study, the outer-capsid proteins VP2 or VP2 and VP5 were reproduced using a baculovirus expression system in Sf9 insect cells. Baculovirus expression systems are a popular choice for producing large quantities of proteins.
  • The reproduced proteins were then used to vaccinate the horses. Different quantities of the proteins were tested to assess the level of immune response generated.
  • The team followed up these vaccinations with a live exposure to AHSV, to measure the vaccine’s protective effects.
  • The results from this research showed that a dose of 5 micrograms or more of these proteins was enough to produce a protective immune response.
  • Even when exposed to a live AHSV infection six months after their vaccination, the horses that were vaccinated showed sufficient protection against the disease.

Concluding Remarks and Future Directions

  • These findings suggest that the VP2 protein, synthesized through recombinant baculovirus, could serve as a potential new vaccine for African horsesickness.
  • The next stages of the research would likely involve further studies to validate these results, potentially using a larger sample of horses and varying conditions to make the findings more robust and generalizable. Additional experimentation would also be needed to check the long-term health impacts of the vaccine on the horses.

Cite This Article

APA
Roy P, Bishop DH, Howard S, Aitchison H, Erasmus B. (1996). Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. J Gen Virol, 77 ( Pt 9), 2053-2057. https://doi.org/10.1099/0022-1317-77-9-2053

Publication

The Journal of general virology
ISSN: 0022-1317
NlmUniqueID: 0077340
Country: England
Language: English
Volume: 77 ( Pt 9)
Pages: 2053-2057

Researcher Affiliations

Roy, P
  • Laboratory of Molecular Biophysics, University of Oxford, UK. por@mail.nerc-oxford.ac.uk
Bishop, D H
    Howard, S
      Aitchison, H
        Erasmus, B

          MeSH Terms

          • African Horse Sickness / immunology
          • African Horse Sickness / prevention & control
          • African Horse Sickness Virus / genetics
          • African Horse Sickness Virus / immunology
          • Animals
          • Antibodies, Viral / blood
          • Antigens, Viral / genetics
          • Antigens, Viral / immunology
          • Capsid / genetics
          • Capsid / immunology
          • Capsid Proteins
          • Cell Line
          • Chick Embryo
          • Horses
          • Neutralization Tests
          • Nucleopolyhedroviruses / genetics
          • Spodoptera / cytology
          • Vaccines, Synthetic / genetics
          • Vaccines, Synthetic / immunology
          • Viral Vaccines / genetics
          • Viral Vaccines / immunology

          Citations

          This article has been cited 20 times.
          1. Moore S, Jukes M. The History of Baculovirology in Africa.. Viruses 2023 Jul 7;15(7).
            doi: 10.3390/v15071519pubmed: 37515205google scholar: lookup
          2. Fairbanks EL, Brennan ML, Mertens PPC, Tildesley MJ, Daly JM. Re-parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search.. Transbound Emerg Dis 2022 Jul;69(4):e671-e681.
            doi: 10.1111/tbed.14420pubmed: 34921513google scholar: lookup
          3. Sullivan E, Lecollinet S, Kerviel A, Hue E, Pronost S, Beck C, Dumarest M, Zientara S, Roy P. Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes.. Vaccine 2021 May 27;39(23):3161-3168.
            doi: 10.1016/j.vaccine.2021.04.034pubmed: 33958224google scholar: lookup
          4. Calvo-Pinilla E, Marín-López A, Utrilla-Trigo S, Jiménez-Cabello L, Ortego J. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design.. Curr Opin Virol 2020 Oct;44:49-56.
            doi: 10.1016/j.coviro.2020.06.003pubmed: 32659516google scholar: lookup
          5. Sunwoo SY, Noronha LE, Morozov I, Trujillo JD, Kim IJ, Schirtzinger EE, Faburay B, Drolet BS, Urbaniak K, McVey DS, Meekins DA, Palmer MV, Balaraman V, Wilson WC, Richt JA. Evaluation of A Baculovirus-Expressed VP2 Subunit Vaccine for the Protection of White-Tailed Deer (Odocoileus virginianus) from Epizootic Hemorrhagic Disease.. Vaccines (Basel) 2020 Jan 31;8(1).
            doi: 10.3390/vaccines8010059pubmed: 32023812google scholar: lookup
          6. Rutkowska DA, Mokoena NB, Tsekoa TL, Dibakwane VS, O'Kennedy MM. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.. BMC Vet Res 2019 Dec 3;15(1):432.
            doi: 10.1186/s12917-019-2184-2pubmed: 31796116google scholar: lookup
          7. Porphyre T, Grewar JD. Assessing the potential of plains zebra to maintain African horse sickness in the Western Cape Province, South Africa.. PLoS One 2019;14(10):e0222366.
            doi: 10.1371/journal.pone.0222366pubmed: 31671099google scholar: lookup
          8. Dennis SJ, Meyers AE, Hitzeroth II, Rybicki EP. African Horse Sickness: A Review of Current Understanding and Vaccine Development.. Viruses 2019 Sep 11;11(9).
            doi: 10.3390/v11090844pubmed: 31514299google scholar: lookup
          9. Aksular M, Calvo-Pinilla E, Marín-López A, Ortego J, Chambers AC, King LA, Castillo-Olivares J. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.. Vaccine 2018 Nov 12;36(46):7003-7010.
            doi: 10.1016/j.vaccine.2018.09.065pubmed: 30309744google scholar: lookup
          10. Lulla V, Losada A, Lecollinet S, Kerviel A, Lilin T, Sailleau C, Beck C, Zientara S, Roy P. Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge.. Vaccine 2017 Jul 24;35(33):4262-4269.
            doi: 10.1016/j.vaccine.2017.06.023pubmed: 28625521google scholar: lookup
          11. Mathebula EM, Faber FE, Van Wyngaardt W, Van Schalkwyk A, Pretorius A, Fehrsen J. B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera.. Onderstepoort J Vet Res 2017 Feb 24;84(1):e1-e12.
            doi: 10.4102/ojvr.v84i1.1313pubmed: 28281773google scholar: lookup
          12. Lulla V, Lulla A, Wernike K, Aebischer A, Beer M, Roy P. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.. J Virol 2016 Aug 15;90(16):7405-7414.
            doi: 10.1128/JVI.00548-16pubmed: 27279609google scholar: lookup
          13. van de Water SG, van Gennip RG, Potgieter CA, Wright IM, van Rijn PA. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.. J Virol 2015 Sep;89(17):8764-72.
            doi: 10.1128/JVI.01052-15pubmed: 26063433google scholar: lookup
          14. Kanai Y, van Rijn PA, Maris-Veldhuis M, Kaname Y, Athmaram TN, Roy P. Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.. Vaccine 2014 Sep 3;32(39):4932-7.
            doi: 10.1016/j.vaccine.2014.07.031pubmed: 25045805google scholar: lookup
          15. de la Poza F, Calvo-Pinilla E, López-Gil E, Marín-López A, Mateos F, Castillo-Olivares J, Lorenzo G, Ortego J. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.. PLoS One 2013;8(7):e70197.
            doi: 10.1371/journal.pone.0070197pubmed: 23894615google scholar: lookup
          16. Lo Iacono G, Robin CA, Newton JR, Gubbins S, Wood JL. Where are the horses? With the sheep or cows? Uncertain host location, vector-feeding preferences and the risk of African horse sickness transmission in Great Britain.. J R Soc Interface 2013 Jun 6;10(83):20130194.
            doi: 10.1098/rsif.2013.0194pubmed: 23594817google scholar: lookup
          17. Manole V, Laurinmäki P, Van Wyngaardt W, Potgieter CA, Wright IM, Venter GJ, van Dijk AA, Sewell BT, Butcher SJ. Structural insight into African horsesickness virus infection.. J Virol 2012 Aug;86(15):7858-66.
            doi: 10.1128/JVI.00517-12pubmed: 22593166google scholar: lookup
          18. Backer JA, Nodelijk G. Transmission and control of African horse sickness in The Netherlands: a model analysis.. PLoS One 2011;6(8):e23066.
            doi: 10.1371/journal.pone.0023066pubmed: 21850252google scholar: lookup
          19. Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PP. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.. PLoS One 2011 Jan 26;6(1):e16503.
            doi: 10.1371/journal.pone.0016503pubmed: 21298069google scholar: lookup
          20. Chiam R, Sharp E, Maan S, Rao S, Mertens P, Blacklaws B, Davis-Poynter N, Wood J, Castillo-Olivares J. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).. PLoS One 2009 Jun 22;4(6):e5997.
            doi: 10.1371/journal.pone.0005997pubmed: 19543394google scholar: lookup
          Subscribe to our newsletter
          Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.